Similar articles

• [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].

  Fukuda A. Fukuda A. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):493-6. Nihon Rinsho. 2004. PMID: 15359848 Review. Japanese. No abstract available.
• [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].

  Serfaty L. Serfaty L. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B202-5. Gastroenterol Clin Biol. 2002. PMID: 12180289 Review. French. No abstract available.
• [Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].

  Iyoda K, Kato M. Iyoda K, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):502-5. Nihon Rinsho. 2004. PMID: 15359850 Review. Japanese. No abstract available.
• Individualisation of antiviral therapy for chronic hepatitis C.

  Teoh NC, Farrell GC, Chan HL. Teoh NC, et al. J Gastroenterol Hepatol. 2010 Jul;25(7):1206-16. doi: 10.1111/j.1440-1746.2010.06392.x. J Gastroenterol Hepatol. 2010. PMID: 20594246 Review.
• SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.

  Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K. Naito M, et al. J Gastroenterol. 2005 Apr;40(4):381-8. doi: 10.1007/s00535-005-1558-3. J Gastroenterol. 2005. PMID: 15868370